Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)
China · Delayed Price · Currency is CNY 5.09
-0.18 (-3.42%)
Aug 24, 2026, 3:04 PM CST
SHE:300006 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 5,375 | 5,427 | 3,865 | 3,928 | 4,023 | 7,201 | |
Market Cap Growth | 4.52% | 40.44% | -1.61% | -2.36% | -44.14% | 19.33% |
Enterprise Value | 4,802 | 4,900 | 3,221 | 3,425 | 3,734 | 6,886 |
Last Close Price | 5.09 | 5.14 | 3.66 | 3.72 | 3.81 | 6.82 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Forward PE | - | 139.34 | 139.34 | 139.34 | 139.34 | 139.34 |
PS Ratio | 7.18 | 7.00 | 4.86 | 4.39 | 4.55 | 5.88 |
PB Ratio | 3.07 | 3.08 | 2.05 | 1.85 | 1.84 | 3.26 |
P/TBV Ratio | 3.45 | 3.44 | 2.34 | 2.11 | 2.11 | 3.59 |
P/FCF Ratio | 346.20 | - | 36.32 | 176.84 | - | 103.43 |
P/OCF Ratio | 106.23 | 208.44 | 20.89 | 48.18 | 70.41 | 66.51 |
PEG Ratio | - | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.41 | 6.32 | 4.05 | 3.82 | 4.22 | 5.62 |
EV/EBITDA Ratio | - | - | - | 391.02 | - | - |
EV/FCF Ratio | 309.29 | - | 30.28 | 154.20 | - | 98.90 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.28 | 0.21 | 0.26 | 0.13 | 0.17 | 0.10 |
Debt / EBITDA Ratio | - | - | - | 16.86 | - | - |
Debt / FCF Ratio | 31.79 | - | 4.65 | 12.19 | - | 3.15 |
Net Debt / Equity Ratio | -0.34 | -0.31 | -0.31 | -0.27 | -0.22 | -0.15 |
Net Debt / EBITDA Ratio | 26.34 | 17.73 | 23.64 | -64.58 | 13.63 | 5.36 |
Net Debt / FCF Ratio | -38.08 | 35.18 | -5.43 | -25.47 | 43.53 | -4.88 |
Asset Turnover | 0.28 | 0.29 | 0.28 | 0.30 | 0.30 | 0.40 |
Inventory Turnover | 2.01 | 1.96 | 1.59 | 1.52 | 1.33 | 1.68 |
Quick Ratio | 1.73 | 1.82 | 1.90 | 2.57 | 2.15 | 2.32 |
Current Ratio | 1.99 | 2.09 | 2.21 | 2.93 | 2.49 | 2.59 |
Return on Equity (ROE) | -6.65% | -6.94% | -4.00% | -0.46% | -3.47% | -6.15% |
Return on Assets (ROA) | -1.54% | -1.79% | -1.63% | -1.19% | -2.21% | -2.75% |
Return on Invested Capital (ROIC) | -5.58% | -6.18% | -5.23% | 9.70% | -5.92% | -6.69% |
Return on Capital Employed (ROCE) | -3.60% | -4.20% | -3.60% | -2.40% | -4.50% | -5.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.36% | -2.48% | -2.27% | -0.23% | -1.71% | -1.40% |
FCF Yield | 0.29% | -0.29% | 2.75% | 0.56% | -0.27% | 0.97% |
Buyback Yield / Dilution | 1.67% | -0.03% | -0.48% | 0.48% | -6.03% | -22.54% |
Total Shareholder Return | 1.67% | -0.03% | -0.48% | 0.48% | -6.03% | -22.54% |